Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis

NCT05716854 is registered in ClinicalTrials.gov with Food and Drug Administration (FDA) as lead sponsor.

NCT NCT05716854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05716854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis
Lead sponsor
Food and Drug Administration (FDA)
Phase
Phase 1
Overall status
Completed
Start date
March 21, 2023
Completion date
June 13, 2023
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug-induced qt prolongation, pharmacodynamics, pharmacokinetics